))
Episode 34: NET Treatments: Focus on PRRT
Manage episode 423672614 series 3426844
Вміст надано Learn Advocate Connect Neuroendocrine Tumor Society. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією Learn Advocate Connect Neuroendocrine Tumor Society або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances.
MEET DR. RIHAM EL KHOULI, MD, PHD
Associate Professor of Radiology, UK College of Medicine
Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics (NM/MI&R)
Director, Radiotheranostics Program
University of Kentucky
Dr. Riham El Khouli, MD PhD, is the director of the Radiotheranostics program and Chief of the division of NM/MI&R at the University of Kentucky and an Associate Professor of Radiology, Nuclear Medicine and Molecular Imaging at UK school of Medicine.
TOP TEN QUESTIONS ABOUT NET TREATMENTS:
1. What is PRRT? How does it work?
2. What is theranostics and what does it mean? What are the terms radiotheranostics, radiopharmaceutical, radioligand therapy, PRRT?
3. How do you determine who is eligible for PRRT?
4. When is PRRT given in one’s treatment journey?
5. How does PRRT differ from other treatments?
6. What are the common side effects of Lutathera?
a. Does Lutathera have long-lasting effects?
b. Would receiving Lutathera affect one’s blood counts?
c. How might Lutathera affect one’s liver function? When, if ever is there concern about liver failure?
7. How might PRRT affect my quality of life and my day-to-day ability to work and function? What is the risk and effects of radiation with receiving Lutathera?
a. What precautions do I need to follow?
b. Can I hug my child? Can I pet my dog?
c. Would receiving Lutathera cause someone to be immunocompromised?
8. How to you decide who should get PRRT?
a. What is peritoneal disease and how effective is PRRT with peritoneal disease?
9. How do you assess the response to PRRT?
10. What advances in PRRT are you most excited about?
Visit https://www.lacnets.org/podcast/34.
For more information, visit LACNETS.org.
41 епізодів
Поширити
